Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The role of anti-IgE (omalizumab) in the management of severe eczema in children
2010-020841-29Phase 4Completed
- Sponsor
- King's College London
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atopic dermatitis (AD) comparing Omalizumab (Xolair) with Placebo (2 arms). Primary endpoint: Objective SCORAD at week 24. Started Apr 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2010-020841-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020841-29.